Research programme: gastro-oesophageal reflux therapy - Nycomed

Drug Profile

Research programme: gastro-oesophageal reflux therapy - Nycomed

Alternative Names: P-CABs - Nycomed

Latest Information Update: 11 Apr 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nycomed
  • Developer Takeda Pharmaceuticals International GmbH
  • Class Imidazoles; Pyridines; Small molecules
  • Mechanism of Action Potassium-competitive acid blockers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Gastro-oesophageal reflux

Most Recent Events

  • 01 Apr 2012 Discontinued - Preclinical for Gastro-oesophageal reflux in Europe (PO)
  • 30 Sep 2011 Nycomed has been acquired by Takeda
  • 02 Apr 2008 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top